compound introduction
Zibotentan (ZD4054) 是一种有效的，选择性的内皮素 A (ETA) 受体拮抗剂，Ki 为 13 nM。Zibotentan 对 ETB 没有抑制作用。Zibotentan 具有抗癌作用，可用于去势抵抗性前列腺癌 (CRPC) 的研究。 Zibotentan has been found to inhibit cell proliferation, invasion and metastasis in cancer models. In clinical trials on patients with castration-resistant prostate cancer and bone metastasis, who were pain-free or had mild pain, zibotentan treatment resulted in better overall survival as compared to placebo.Zibotentan is a potent and selective endothelin ET(A) receptor antagonist with an IC50 of 21 nM for the ETA receptor subtype and no binding observed even at 10,000 nM for ETB.
